RAD51-Inhibitor-B02-SDS-MedChemExpress
EL-102_SDS_MedChemExpress
Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:May-24-2017Print Date:May-24-20171. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :EL-102Catalog No. :HY-16187CAS No. :1233948-61-21.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureNot a hazardous substance or mixture.2.2 GHS Label elements, including precautionary statementsNot a hazardous substance or mixture.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:EL 102; EL102Formula:C19H16N2O3S2Molecular Weight:384.47CAS No. :1233948-61-24. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Powder-20°C 3 years4°C 2 yearsIn solvent-80°C 6 months-20°C 1 monthShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance Light yellow to yellow (Solid)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGThis substance is considered to be non-hazardous for transport.IATAThis substance is considered to be non-hazardous for transport.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2017 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。
体外细胞实验方法
细胞株在适当的培养基中保持10% FBS。
从Addgene(质粒)购买HA-FLAG-UCHL3。
#22564,然后再克隆到pGEX-4T-2载体(Clontech)中。
UCHL3C94A和S75A突变体由位点定向突变层积产生)。
抗uchl3抗体购自ProteinTech公司(12384 - 1 - ap)。
抗ub (P4D1)、抗rpa32 (9H8)、抗brca1 (D9)抗体购自Santa Cruz Biotechnology。
抗rad51 (N1C2)是从GeneTex购买的。
反γH2AX(05 - 636),anti-BRCA2(OP95)和anti-MDC1(05 - 1572)从微孔被购买。
Anti-BRCA2(推上a303国道- 435 a)和anti-γH2AX架a300型(- 081 a)从Bethyl购买实验室。
抗53bp1 (NB100-304)购自Novus Biologicals。
Anti-Flag(m2)、anti-HA anti-β-actin抗体购买的σ。
反磷(血清/thr)atm/atr衬底抗体(2851)是从细胞信号技术中购买的。
CRISPR / Cas9敲除(sgRNAs)使用:sgUCHL3-1(5′-GCCGCTGGAGGCCAATCCCGAGG-3′)和sgUCHL3-2(5′-GCCCCGAAGCGCGCCCACCTCGG-3′)。
gRNA序列被克隆到载体中。
LentiCRISPR-V2-puro。
细胞被慢病毒感染sgRNA-puro随后与2μg /毫升嘌呤霉素广泛的选择,和单一的克隆是通过连续稀释和放大。
通过免疫印迹鉴定克隆抗uchl3抗体,并通过DNA测序验证。
重组蛋白表达和下拉试验。
构建表达His-RAD51和GSTUCHL3蛋白的质粒,构建RAD51和UCHL3的编码序列被亚克隆为pET-32a和pGEX-4T-2。
为了产生重组蛋白,每个表达结构都转化为大肠杆菌BL21 (DE3)。
地高辛标记及检测试剂盒说明书
仅仅研究于生命科学,不适合在诊断过程使用只能在体外使用地高辛DNA标记和检测试剂盒1和NBT/BCIP一起用于颜色检测通过酶联免疫法采用地高辛-dUTP进行随机引物DNA标记,碱性标记和检测货号:11 745 832 910此试剂盒储存条件-15o C—-25o C此试剂盒可对10ng-3ugDNA进行12次标记反应可检测100cm2面积的杂交膜24张指导手册2009.11版1前言1.1内容表1前言 (2)1.1内容表 (2)1.2试剂盒内容 (3)2简介 (5)2.1产品概述 (5)3步骤和所需材料 (8)3.1开始之前 (8)3.2地高辛DNA标记 (9)3.3 标记效率的测定 (11)3.4 DNA 的转移和固定 (14)3.5杂交 (16)3.6免疫检测 (18)3.7 DNA印记的洗脱和再杂交 (20)4结果 (21)4.1典型的结果 (21)5附录 (23)5.1故障排除 (23)5.2引用 (24)5.3订购信息 (25)1.2 试剂盒内容附加仪器与所需试剂除了上表中列出的试剂外,你必须准备一些溶液。
在下表中,你可以找到不同操作程序需要准备的设备概要。
*标记的产品可以从Roche Applied Science 获得2 介绍2.1 产品概况实验原则此试剂盒采用地高辛(DIG),一种甾类半抗原,去标记DNA探针从而通过酶免疫分析应用地高辛标记DNA探针可以用于:所有类型的滤膜杂交总基因组DNA中单拷贝基因的检测,甚至对于高度复杂的生物也可以进行检测,如人,大麦和小麦。
样品材料至少100bp的DNA片段线性的质粒,cos质粒或者λDNA超螺旋的DNA实验时间此表格列出了每一步实验所需的反应时间检测数量一个试剂盒足够用于:不超过3ug的模板DNA的12个标准的标记反应和100cm2有24个斑点的检测质量控制根据操作步骤中的描述,对未标记的对照品DNA(PBR328)进行标记,0.1pg同源DNA 在点杂交中通过16h的显色来检测(1pg同源DNA可以通过1小时的显色进行检测)。
R&D常见问题之细胞凋亡检测
R&D常见问题之细胞凋亡检测问:为什么有两套不同的TUNEL试剂盒?答:因为有两种不同的TUNEL方法可检测细胞凋亡。
第一种方法采用TdT酶(末端脱氧核苷酸转移酶)将生物素化的核苷酸加到组织中的DNA片段的3'-羟基端。
加入正离子可使这种标记更有效,经生物素化的核苷酸可用streptavidin-HRP共轭物和底物来检测。
第二种方法仍采用TdT酶(末端脱氧核苷酸转移酶)将核苷酸加到样本中的DNA片段的3'-羟基端,但采用5-溴脱氧尿苷(BrdU)标记而非生物素,再用生物素化的抗5-溴脱氧尿苷(BrdU)抗体来检测。
采用这种方法的细胞凋亡检测试剂盒包括:TA100 TACS-XL基本原位细胞凋亡试剂盒;TA200 TACS-XL DAB原位细胞凋亡试剂盒;TA300 TACS-XL蓝色标记原位细胞凋亡试剂盒;TA400 TACS-XL补充细胞凋亡试剂盒;问:Caase活性测试是如何使用的?答:Caase活性测试为在细胞裂解液中检测蛋白酶活性提供了简捷方便的手段。
当对专一Caase的多肽底物被裂解时,释放出的指示分子可用普通读光仪或荧光读板仪来做定量测定。
将从细胞凋亡样本得到的信号同未经诱导的对照样本进行比较,可以确定Caase活性增加的倍数,而Caase酶活性是同检测到的信号直接成正比。
问:Caase活性测试是否可用于定量检测?答:R&D Systems的Caase活性测定试剂盒可作为半定量测试。
检测结果最好用于测量在细胞凋亡细胞中与未经诱导细胞中的Caase活性倍数的增加。
实验时,最好采用本底对照(无细胞裂解液或无底物的反应)。
如果本底对照也有一定的读数,这一读数应当在记算倍数增加之前从试验数据中差减。
问:Caase活性检测同Caase ELISA试剂盒有何不同?答:Caase活性检测用于测定不同Caase的蛋白酶的活性,表达为比未诱导样本的倍数增加。
Caase ELISA试剂盒用于测定不同Caase在样本中的含量,以pg /mL定量表达。
5β地中海贫血基因检测试剂盒(荧光PCR法)产品说明书--20190301雷彩霞修改
β-地中海贫血基因检测试剂盒(荧光PCR法)说明书【产品名称】通用名称:β-地中海贫血基因检测试剂盒(荧光PCR法)【包装规格】24人份/盒【预期用途】本试剂盒用于定性检测β-地中海贫血基因突变情况,以EDTA抗凝全血为检测样本,适用于临床β-地中海贫血基因突变的诊断。
β-地中海贫血是一组遗传性疾病,其临床表现多样,由轻到重,甚至危及生命,导致患者在未成年即夭折甚至胎死腹中,给家庭和社会带来巨大的负担。
且目前尚无根治手段,国内外都没有疗效标准。
因此控制和降低β-地中海贫血患儿的出生率才能有效地监控该病的发生,通过人群筛查和遗传咨询,对有携带β地贫基因的孕龄夫妇所孕胎儿实施产前诊断,是目前最有效的控制重症β-地中海贫血患儿出生的方法。
【检验原理】本试剂盒能够检测24种β-地中海贫血基因类型(具体信息见附表1),采用八联PCR管进行检测,12管一人份,共12支扩增液(扩增液检测突变类型及对应的荧光通道信息详见附表2),每个反应管检测两种突变型和两种野生型,分别通过四个不同的荧光通道读取信息。
根据文献,我们参照人类β-地中海贫血基因情况以包括突变情况的一段基因序列作为靶序列,设计特异性突变检测引物探针、特异性野生型检测引物探针,采用基因扩增技术对核酸特异性基因进行检测。
突变型情况由FAM、HEX指示,野生型情况由ROX、CY5指示,对β-地中海贫血基因进行特异性检测,为临床检验提供实验室辅助诊断的依据。
本试剂盒使用核酸提取试剂提取基因组DNA。
试剂盒添加了防污染成分UNG酶,UNG酶可将反应体系中已有的U-DNA污染物中的尿嘧啶碱基降解,并在随后变性这步的条件下DNA链断裂,消除由于污染DNA产生的扩增,保证扩增结果的特异性,准确性。
【主要组成成分】试剂盒1:编号扩增液类型规格数量引物探针类型1 β地贫1 扩增液24人份/支1支41-42M引物探针,IVS-Ⅱ-5M引物探针2 β地贫2扩增液24人份/支1支654M引物探针,43M引物探针3 β地贫3扩增液24人份/支1支26M引物探针,30M引物探针4 β地贫4扩增液24人份/支1支27-28M引物探针,IVS-1-1M(T)引物探针5 β地贫5扩增液24人份/支1支31M引物探针,-28M引物探针6 β地贫6扩增液24人份/支1支17M引物探针,-29M引物探针7 β地贫7扩增液24人份/支1支IVS-1-1M(A)引物探针,71-72M(A)引物探针8 β地贫8扩增液24人份/支1支14-15M引物探针,41M引物探针9 β地贫9扩增液24人份/支1支IVS-1-5M引物探针,71-72M(T)引物探针10 β地贫10扩增液24人份/支1支-31M引物探针,CAP40-43M引物探针11 β地贫11扩增液24人份/支1支IntM引物探针,-32M引物探针12 β地贫12扩增液24人份/支1支CAP-1M引物探针,-30M引物探针组成成分生化组成规格数量H-2应缓冲液4-羟乙基哌嗪乙磺酸、氯化钾、氯化镁、硫酸铵、甲酰胺、脱氧核糖核苷三磷酸1.5mL/支4支A酶混合液Taq DNA聚合酶、尿嘧啶糖基化酶、酶储存液A 50μL /支3支稀释缓冲液三羟甲基氨基甲烷盐酸盐、三羟甲基氨基甲烷 1.5mL/支6支TE缓冲液三羟甲基氨基甲烷盐酸盐、三羟甲基氨基甲烷、乙二胺四乙酸二钠盐1.5mL/支2支石蜡油 1.5mL/支5支试剂盒2:组成成分生化组成规格数量β地贫阴性对照生理盐水500μL/支1支β地贫阳性对照质粒500μL/支1支注:本试剂盒由试剂盒1和试剂盒2组成。
常用蛋白酶切割位点
Leu-Glu-Val-Leu-Phe-Gln▼Gly-Pro
L-E-V-L-F-Q▼G-P
Novagen
Ni-NTA (6His recomb. enzyme)
SUMO Protease
recognize the tertiary structure of the ubiquitin-like (UBL) protein, SUMO
Amersham-Biosciences, Novagen,
SIGMA, Roche
Benzamidine-Agarose
Factor Xa
Ile-Glu/Asp-Gly-Arg▼?
I-E/D-G-R▼
Amersham-Biosciences,
New England Biolabs,
Roche
Benzamidine-Agarose
Invitrogen – Life Technologies
Ni-NTA (6His recomb. TEV)
PreScission
Leu-Glu-Val-Leu-Phe-Gln▼Gly-Pro
L-E-V-L-F-Q▼G-P
Amersham-Biosciences
GSTrap for GST fusion enzyme
KEX2对arg的专一性高,要求最重要。
Arg前为lys效率最高,不切-Arg-lys,Pro影响KEX2切割
羧肽酶
羧肽酶B可以切割C端的Lys或Arg;羧肽酶A可以切割C端除了Lys、Arg、Pro的氨基酸,但如果倒数第二个氨基酸为Pro两种羧肽酶均不能作用
1.胰蛋白酶属肽链内切酶,能把多肽链中Lys和Arg残基中的羧基侧切断。
丙二醛检测试剂盒(TBA比色法)
丙二醛(MDA)检测试剂盒(TBA比色法)简介:动物或植物细胞发生氧化应激(oxidative stress)时,会发生脂质氧化。
丙二醛(Malondialdehyde, MDA)是一种生物体脂质氧化的天然产物,一些脂肪酸氧化后逐渐分解为一系列包括MDA在内的复杂化合物,此时通过检测MDA的水平即可检测脂质氧化的水平,因此MDA的测定被广泛用作脂质氧化的指标。
丙二醛(MDA)检测试剂盒(TBA比色法,MDA Assay Kit)又称脂质氧化(MDA)检测试剂盒,是采用一种基于MDA和硫代巴比妥酸(thiobarbituric acid, TBA)反应产生红色产物的显色反应,广泛用于脂质氧化(lipid peroxidation)水平检测。
丙二醛在较高温度及酸性环境中可与TBA发生反应,形成红色的MDA-TBA加合物,MDA-TBA加合物在535nm 处有最大吸收,据此可以通过比色法进行检测。
本试剂盒仅用于科研领域,不宜用于临床诊断或其他用途。
组成:操作步骤(仅供参考):1、样本处理:①血清、血浆、尿液、脑脊液样本:从待测样本中分理出的血清或血浆不应有溶血,直接检测,如超过线性范围,用生理盐水稀释后检测。
②组织、细胞等样本:组织或细胞可以使用PBS或Leagene Western及IP细胞裂解液等进行匀浆或裂解。
匀浆或裂解组织时,组织重量占匀浆液或裂解液的比例应为10%。
样品准备完毕后可以用BCA蛋白浓度测定试剂盒测定蛋白浓度,以便于后续计算单位蛋白重量组织或细胞内的MDA含量。
本试剂盒对于样品中的常见化学成分的兼容性参考下表:试剂类别化学成分是否干扰缓冲液HEPES (100mM) 否Borate (50mM) 否Phosphate (100mM) 否编号名称TO101350TTO1013100TStorage试剂(A): TBA 0.4g 0.8g RT 避光试剂(D): MDA标准品(1mmol/L) 0.1ml 0.2ml -20℃避光试剂(E): MDA检测液5ml 10ml RT试剂(F): MDA分离液150ml 300ml RT 避光使用说明书说明书Tris (25mM) 否去垢剂CHAPS (≤1%) 否Triton X-100 (≤1%) 否Tween 20 (≤1%) 否抑制剂/螯合剂PMSF (≤200μM) 否EDTA (≤1mM) 否EGTA (≤1mM) 否Antipain (≤100μg/ml) 否Chymostatin (≤10μg/ml) 否Leupeptin (≤10μg/ml) 否Trypsin (≤10μg/ml) 否其他Glycerol (≤10%) 否Sucrose (250mM) 是2、TBA工作液的配制:TBA工作液。
海肾荧光素酶检测系统 - 普洛麦格(北京)生物技术有限公 …
海肾荧光素酶检测系统
产品包装目录号价格
Renilla Luciferase Assay System 100次
1,000次E2810 E2820
描述:普洛麦格公司的海肾荧光素酶检测系统设计了快速灵敏的方法,检测来自海洋动物海肾(Renilla reniformis)的荧光素酶。
这些系统可方便地替代萤火虫 (Photinus pyralis) 报告基因系统,得到可靠的、线性范围超过7个数量级酶浓度的结果。
与其它试剂相比,获得专利的海肾荧光素酶检测系统组分配方显著降低了腔肠素(coelenterazine) 的自发荧光影响,比已发表的方法灵敏度高几个数量级。
这些系统可测量野生型的或合成的hRluc基因作为主要表达基因,或作为内标测量基因的表达。
海肾荧光素酶检测系统包括海肾裂解液,海肾荧光素酶检测缓冲液和海肾荧光素酶检测底物。
特点:
●降低的自发荧光:低背景,高灵敏度
●灵敏度:可检测10-19摩尔的海肾荧光素酶
●线性:线性范围超过7个数量级
●独特:第一个,也是唯一的海肾荧光素酶检测试剂盒
操作手册:
技术手册: TM055
储存条件:储存海肾荧光素酶检测系统于-20℃。
储存海肾荧光素酶检测底物于-20℃,或-70℃至18个月。
Promega公司荧光素酶技术系列产品指南。
碧云天生物技术 Beyotime Biotechnology 产品说明书
碧云天生物技术/Beyotime Biotechnology订货热线:400-168-3301或800-8283301订货e-mail:******************技术咨询:*****************网址:碧云天网站微信公众号MuERVL-Gag Rabbit Polyclonal Antibody产品编号产品名称包装AF0240 MuERVL-Gag Rabbit Polyclonal Antibody 50μl产品简介:来源用途交叉反应性分子量Rabbit ICC, IF M 67KDa WB, Western blot; IP, Immunoprecipitation; IF, Immunofluorescence; IHC, Immunohistochemistry; ICC, Immunocytochemistry;FC, Flow Cytometry; ELISA, Enzyme-linked Immunosorbent Assay; ChIP, Chromatin Immunoprecipitation Assay.H, Human;M, Mouse; R, Rat; C, Chicken; Cw, Cow; Dg, Dog; Gp, Guinea pig; Hm, Hamster; Hr, Horse; Mk, Monkey; Pg, Pig;Rb, Rabbit; S, Sheep; Z, Zebrafish; All, all species expected.配套提供了Western一抗稀释液,可以用于Western检测或其它适当用途时的一抗稀释。
建议抗体使用时的稀释比例如下(实际使用时需根据抗原水平的高低作适当调整):WB IP IF IHC ICC FC ELISA ChIP- - 1:200 - 1:200 - - -抗体详细信息如下:About this AntibodyName MuERVL-Gag Rabbit Polyclonal AntibodyCategory Polyclonal antibody(pAb); Primary antibodyIsotype IgGPurification Peptide affinity purifiedAbout the ImmunogenImmunogen This antibody is produced by immunizing rabbits with a synthetic peptide (KLH-coupled) corresponding to MuERVL-Gag.Gene ID - SwissProt - Synonyms - CategoryBackground A large number of retrotransposons are expressed when the zygotic genome is first transcribed, including the endogenous retroviruses (ERVs), LINE-1 elements, and the non-autonomous SINE elements. At the 2C stage, MuERV-L/MERVL retrovirus-like elements are transiently de-repressed and produce 3% of the transcribed mRNAs. Following the 2C stage, MERVL-retroelement expression is silenced. The newly study discovered that this regulated pattern of MERVL expression overlapped with greater than one hundred 2C-specific genes that have co-opted regulatory elements from these foreign retroviruses to initiate their transcription.包装清单:产品编号产品名称包装AF0240 MuERVL-Gag Rabbit Polyclonal Antibody 50μlAZ050 Western一抗稀释液50ml-说明书1份保存条件:MuERVL-Gag Rabbit Polyclonal Antibody -20ºC保存,Western一抗稀释液-20ºC或4ºC保存,一年有效。
溶菌酶的提取,分离纯化,产物纯度鉴定及活性测定
溶菌酶的提取,分离纯化,产物纯度鉴定及活性测定实验目的:1、学习和掌握溶菌酶的制备过程2、学习和掌握溶菌酶的纯化过程3、学习和掌握聚丙烯酰胺凝胶电泳的德原理和技术4、测定溶菌酶的分子量和所提取的溶菌酶的浓度5、测定所提取的溶菌酶的活性试验原理:溶菌酶(lysozyme)又称胞壁质酶(muramidase)或N-乙酰胞壁质聚糖水解酶(N-acetylmuramide glycanohydrlase),是一种能水解致病菌中黏多糖的碱性酶。
主要通过破坏细胞壁中的N-乙酰胞壁酸和N-乙酰氨基葡糖之间的β-1,4糖苷键,使细胞壁不溶性黏多糖分解成可溶性糖肽,导致细胞壁破裂内容物逸出而使细菌溶解。
溶于水,不溶于乙醚和丙酮,pI为11.0-11.35,最适pH值6.5。
酸性介质中可稳定存在,碱性介质中易失活。
溶菌酶还可与带负电荷的病毒蛋白直接结合,与DNA、RNA、脱辅基蛋白形成复盐,使病毒失活。
因此,该酶具有抗菌、消炎、抗病毒等作用。
该酶广泛存在于人体多种组织中,鸟类和家禽的蛋清、哺乳动物的泪、唾液、血浆、尿、乳汁等体液以及微生物中也含此酶,其中以蛋清含量最为丰富。
从鸡蛋清中提取分离的溶菌酶是由18种129个氨基酸残基构成的单一肽链。
它富含碱性氨基酸,有4对二硫键维持酶构型,是一种碱性蛋白质,其N端为赖氨酸,C端为亮氨酸。
可分解溶壁微球菌、巨大芽孢杆菌、黄色八叠球菌等革兰阳性菌。
2.1、离子交换层析离子交换层析是依据混合样品中各种离子或离子化合物与离子交换树脂的可交换离子之间的交换程度不同而进行分离纯化的。
离子交换层析主要是离子交换剂与溶液中离子或离子化合物以离子交换方式进行,过程是可逆的。
由于离子交换剂对溶液中各种离子具有不同的结合力,也就是说,离子交换剂对各离子的排斥和阻滞作用不同,从而引起各离子在柱内的流速差异,逐渐发生分离,最终分别流出层析柱。
该法可同时分析多种离子化合物,具有灵敏度高,重复性、选择性好,分离速度快等优点。
- 1、下载文档前请自行甄别文档内容的完整性,平台不提供额外的编辑、内容补充、找答案等附加服务。
- 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
- 3、如文档侵犯您的权益,请联系客服反馈,我们会尽快为您处理(人工客服工作时间:9:00-18:30)。
Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:Oct.-03-2018Print Date:Oct.-03-20181. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :RAD51 Inhibitor B02Catalog No. :HY-101462CAS No. :1290541-46-61.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureNot a hazardous substance or mixture.2.2 GHS Label elements, including precautionary statementsNot a hazardous substance or mixture.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:B02Formula:C22H17N3OMolecular Weight:339.39CAS No. :1290541-46-64. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Powder-20°C 3 years4°C 2 yearsIn solvent-80°C 6 months-20°C 1 monthShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance Light yellow to yellow (Solid)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGThis substance is considered to be non-hazardous for transport.IATAThis substance is considered to be non-hazardous for transport.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2018 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。